bêta
IA Trial Radar
L'essai clinique NCT07234656 (PP-RECURK) pour Peur de la récidive du cancer, Renal Cell Carcinoma (Kidney Cancer) est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer (PP-RECURK)

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT07234656 (PP-RECURK) est un essai observationnel pour Peur de la récidive du cancer, Renal Cell Carcinoma (Kidney Cancer). Son statut actuel est : en recrutement. L'étude a débuté le 30 septembre 2025 et vise à recruter 105 participants. Dirigé par Brigitta Rasmussen Villumsen, l'essai devrait être terminé d'ici le 1 janvier 2027. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 18 novembre 2025.
Résumé succinct
The goal of this observational study is to gather real-world information about Fear of Cancer Recurrence (FCR) following surgery in patients with renal cell carcinoma (RCC) and their partners/spouses by 1) establishing a panel consisting of patients with or without partners/spouses to facilitate patient-partnered research. Furthermore, 2) Through discussions among panel members and researchers identification of the most pertinent topics related to FCR, as well as the optimal timing and methods for collecting that information in the follow-up care after surgery. Finally, to conduct a feasibility and pilot study to investigate the feasibility of the recommendations developed in 1) + 2) and assess FCR in patients with RCC following surgery and their partners/spouses.

In phase 1 participants (panel members) will be asked to collaborate with researchers in the development of recommendations for FCR questions, mode of administration and timing in the follow-up care after surgically treated kidney cancer.

In phase 2 participants (patients and partners) in follow-up care after surgically treated kidney cancer are asked to answer questions about FCR at specific timepoints defined by panel members and researchers in phase 1.

Description détaillée
Rationale Previously, Fear of Cancer Recurrence (FCR) has been investigated in patients with renal cell carcinoma (RCC) showing that FCR is the most common source of frustration, and the prevalence of FCR has been estimated to be 54% in patients with localized RCC.

Studies in families with cancer show that approximately 50% of family caregivers experience FCR.

Patient involvement in research is much requested, however, no study to date has involved patients and partners/spouses in the investigation of FCR in patients with kidney cancer and their family caregivers.

Therefore, in this study the investigators will ask patients with localized kidney cancer and their partners/spouses to contribute with their perspectives on what questions to ask in the follow-up care after surgery for kidney cancer to identify FCR. For this purpose, the validated 42-item Fear of Cancer Inventory (FCRI) will be used for inspiration. A caregiver version of the FCRI exists, but has not been translated to Danish and thus translation will be conducted in this study.

This study is expected to provide information to clinicians on how to comply with the European Association of Urology guideline that recommends psychological evaluation for all patients diagnosed with RCC and involvement of patients in adjuvant RCC treatment decisions. Furthermore, the investigators conduct this study to give patients with kidney cancer and partners/spouses a voice in the investigation of FCR in the clinical follow-up care after surgery. This provides an opportunity for a collaboration between patients, partners, patients associations and professional researchers to identify the most appropriate FCR questions, timing, and mode of administration to optimize patient adherence/compliance and treatment outcomes.

Method The project has two phases. Phase 1: Establishment of a patient/partner panel who in collaboration with researchers will use the 5-stage Design thinking model to develop recommendations for investigating FCR in patients and their partners/spouses in follow-up care after surgically treated kidney cancer.

The Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework described by Glasgow et al. will be applied for the process evaluation of recruitment and eligibility of panelists.

The level of meaningful patient/partner/spouse engagement in the project will be evaluated using the Patient Engagement in Research Scale (PEIRS-22).

Phase 2:

The recommendations produced in phase 1 will be tested in a pilot and feasibility study along with investigation of additional factors possibly affecting fear of cancer recurrence in patients and their partners/spouses. All evaluations will be done statistically.

Perspectives If the phase 2 pilot-study turns out successfully in defining FCR in patients with RCC and their partners/spouses, the researchers will seek to perform a national follow-up study, that can constitute a foundation for implementation of FCR as part of standard clinical practice, e.g. detecting when FCR reaches a level that needs interference such as psychological counselling etc.

Titre officiel

Patient-partnered Research: a Key to Investigating Fear of Cancer Recurrence in Patients With Surgically Treated Kidney Cancer (PP-RECURK)

Conditions
Peur de la récidive du cancerRenal Cell Carcinoma (Kidney Cancer)
Publications
Articles scientifiques et travaux de recherche publiés sur cet essai clinique:
Autres identifiants de l'essai
  • PP-RECURK
  • 1-16-02-314-25
Numéro NCT
Date de début (réel)
2025-09-30
Dernière mise à jour publiée
2025-11-18
Date de fin (estimée)
2027-01
Inscription (estimée)
105
Type d'essai
Observationnel
Statut
En recrutement
Mots clés
Fear of Cancer Recurrence
Patient involvement in research
Kidney cancer
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
Panel members
6 patients with spouses/partners and 3 single patients. In total 15 subjects.
Phase 1: Establishment of a Patient-partner Panel
Phase 1: Establishment of a patient-partner panel who in collaboration with researchers define Fear of Cancer Recurrence questions, mode of administration and timing for investigating Fear of Cancer Recurrence in phase 2 (pilot testing in a feasibility study).
Pilot population
In total 90 subjects (patients with or without partners)
Phase 2: Feasibility Testing of FCR Questions, Mode of Administration and Timing for Investigating Fear of Cancer Recurrence
As the intervention for phase 2 is a product of the collaboration and discussions between panel members and researchers during phase 1, the intervention can not be described more detailed.
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Phase 1: Assessment of the recruitment to and composition the patient-partner panel
The RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework will be applied for the assessment of the recruitmentprocess, eligibility of panelists and their representativity.
From inclusion to week 16 or date of last subject included whichever comes first.
Phase 1: Assessment of the degree of patient and partner/spouse involvement
The Patient Engagement in Research Scale (PEIRS) will be applied to assess the degree of meaningful patient and family caregiver engagement in research from a patient and partner/spouse perspective. The 22-item Patient Engagement in Research Scale (PEIRS) score ranges from 0-88. Minimum value per item: 0 (Strongly Disagree), maximum value per item: 4 (Strongly Agree). Higher scores = better engagement in research. To make interpretation easier, many studies convert the raw total to a 0-100 score calculated by taking the total sum score, divided by 88 (22 items X 4 scores), and multiplying it by 100
From inclusion to week 26 or end of engagement whichever comes first.
Phase 2: To investigate whether the recommendations for timing, instructions, mode of administration and Fear of Cancer Recurrence questions stated in phase 1 are feasible in a clinical setting,
Patients' and partners/spouses' compliance to the investigation of Fear of Cancer Recurrence will be evaluated using descriptive statistics. Fulfillment of the feasibility criteria are met when 80% of the included subjects complete the pilot testing.
From inclusion to week 52.
Phase 2: The prevalence of Fear of Cancer Recurrence in single patients with localized Renal Cell Carcinoma
Descriptive statistics will be used to present the level of Fear of Cancer Recurrence. Data will be presented as median Fear of Cancer Recurrence score with 95% Confidence Interval.
From inclusion to week 52 or when the subject withdraws from the study whichever comes first.
Phase 2: The prevalence of Fear of Cancer Recurrence in patients with localized Renal Cell Carcinoma and living in a relationship with a partner/spouse.
Descriptive statistics will be used to present the level of Fear of Cancer Recurrence. Data will be presented as median Fear of Cancer Recurrence score with 95% Confidence Interval.
From inclusion to week 52 or when the subject withdraws from the study whichever comes first.
Phase 2: The prevalence of Fear of Cancer Recurrence in partners/spouses to patients with localized Renal Cell Carcinoma.
Descriptive statistics will be used to present the level of Fear of Cancer Recurrence. Data will be presented as median Fear of Cancer Recurrence score with 95% Confidence Interval.
From inclusion to week 52 or when the subject withdraws from the study whichever comes first.
Critère secondaire d'évaluation
Critères d'évaluationDescription de critèresPériode
Phase 2: Associations between data on Fear of Cancer Recurrence and disease stage in single patients.
Logistic regression analysis will be conducted to investigate associations between Fear of Cancer Recurrence and disease stage: Leibovich disease risk groups (low, medium, and high) . The Fear of Cancer Recurrence Inventory will be used to measure Fear of Cancer Recurrence (FCR). Higher score means higher FCR. The score range from 0-168.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and comorbidity burden in single patients.
Logistic regression analysis will be conducted to investigate associations between Fear of Cancer Recurrence and Charlson Comorbidity Index score. The Fear of Cancer Inventory will be used to measure FCR. Higher score means higher FCR. The score ranges from 0-168.
From inclusion to the study to week 52 or when the subject withdraws consent whichever comes first.
Phase 2: Associations between data on Fear of Cancer Recurrence and sex in single patients.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and age in single patients.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and educational level in single patients.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and disease stage in patients with a partner/spouse.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and comorbidity burden in patients with a partner/spouse.
Logistic regression analyses will be conducted to investigate associations between Fear of Cancer Recurrence score and Charlson Comorbidity Index score.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and sex in patients with a partner/spouse.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and age in patients with a partner/spouse.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and educational level in patients with partner/spouse.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and patients' disease stage in partners/spouses of non-single patients.
Logistic regression analyses will be conducted to investigate associations between data on Fear of Cancer Recurrence and patients' disease stage: Leibovich disease risk groups (low, medium, and high).
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and partners'/spouses' comorbidities in partners/spouses of non-single patients.
Logistic statistical analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and sex of partners/spouses among non-single patients.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and age of partners/spouses among non-single patients.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Phase 2: Associations between data on Fear of Cancer Recurrence and educational level in partners/spouses of non-single patients.
Logistic regression analyses will be conducted to investigate associations.
From inclusion to week 52.
Critères d'éligibilité

Âges éligibles
Enfant, Adulte, Adulte âgé
Sexes éligibles
Tous
Accepte les volontaires en bonne santé
Oui

Phase 1:

  • Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner/spouse
  • Partner/spouse to patients who fullfil the inclusion criteria
  • Patients have undergone surgery due to localized RCC (T1-T2-T3 tumor)
  • Time since surgery: 0-120 months
  • Danish speaking patients and partners/spouses. Must be able to speak, write and read Danish
  • Patients/partners/spouses able to and willing to attend online project meetings or in person at Gødstrup Hospital.

Phase 2:

  • Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner/spouse
  • Partner/spouse to patients who fullfill the inclusion criteria
  • Patients who have undergone surgery due to localized RCC (T1-T2-T3 tumor)
  • Danish speaking patients and partners/spouses. Must be able to speak, write and read Danish
  • Able to receive digital communication from the hospital
  • Informed consent must be signed before answering Fear of Cancer Recurrence questions

Both phases, both patients and partners/spouses:

  • Diagnosed with cognitive impairment
  • Untreated psychiatric disorders due to non-compliance

Phase 2:

• Patients and partners/spouses who were panelists in phase 1

Brigitta Rasmussen Villumsen logoBrigitta Rasmussen Villumsen
Partie responsable de l'essai
Brigitta Rasmussen Villumsen, Promoteur-Investigateur, Principal Investigator, Gødstrup Hospital
Contact central de l'essai
Contact: Brigitta R Villumsen, PhD, +45 20487820, [email protected]
Contact: Anne H Nielsen, PhD, +45 2015 8924, [email protected]
3 Centres de l'essai dans 1 pays
Aalborg University Hospital, Aalborg, 9000, Denmark
Tommy K Nielsen, PhD, Contact, +45 97656359, [email protected]
Pas encore en recrutement
Aarhus University Hospital, Aarhus, 8200, Denmark
Anna K Keller, PhD, Contact, + 45 2029 8015, [email protected]
En recrutement
Gødstrup Hospital, Herning, 7400, Denmark
Mette S Olesen, MSN, Contact
Brigitta R Villumsen, PhD, Contact, +45 20487820
Charlotte G Jensen, PhD, Investigateur principal
Pas encore en recrutement